News|Videos|October 17, 2023

EP. 15: Subsequent Treatment Considerations for Patients with Unsatisfactory Responses to Third-Line Therapy for OAB

Author(s)Benjamin M. Brucker, MD, Eman A. Elkadry, MD, Jenna K. Horton, NP

Experts close their panel on OAB by identifying treatment pathways for patients who have an unsatisfactory response to third-line therapy.

Please see full Prescribing Information for onabotulinumtoxinA, including Boxed Warning.

Sponsored by AbbVie US Medical Affairs

Episodes in this series

EP. 1 In-Clinic Educational Resource on the OAB Treatment Pathway

EP. 1 In-Clinic Educational Resource on the OAB Treatment Pathway

Experts on OAB

EP. 2 EP. 1: An Introduction of the Speakers

Expert on OAB

EP. 3 EP. 2: The Diagnostic Process of OAB and Initial Patient-Clinician Conversations

Expert on OAB

EP. 4 EP. 3: The Typical Patient with OAB and Common Signs and Symptoms

Expert on OAB

EP. 5 EP. 4: The Role of Urodynamic Testing in OAB Evaluation

Experts on OAB

EP. 6 EP. 5: OAB Treatment: Available Strategies and Rationale for Use

Expert on OAB

EP. 7 EP. 6: Factors Informing Selection of Pharmacologic Treatment for OAB

Expert on OAB

EP. 8 Ep. 7: Defining Pharmacologic Treatment Failure in Patients with OAB and Subsequent Treatment Strategies

Expert on OAB

EP. 9 EP. 8: Patient-Clinician Conversations Regarding Initial Pharmacologic Treatment for OAB

Experts on OAB

EP. 10 EP. 9: Treatment Goals and Educational Resources for Patients on Initial Pharmacologic Therapy for OAB

Expert on OAB

EP. 11 EP. 10: Third-Line OAB Therapies and Patient-Centered Decision-Making

Expert on OAB

EP. 12 EP. 11: Setting Treatment Expectations for Patients with OAB Receiving Third-Line Therapies

Expert on OAB

EP. 13 EP. 12: OAB Patient Monitoring and Followup Considerations in the Third-Line Treatment Setting

Experts on OAB

EP. 14 EP. 13: Re-Treatment and Scheduling with OnabotulinumtoxinA

Expert on OAB

EP. 15 EP. 14: SNM and PTNS for OAB: Device Management and Followup

Expert on OAB

EP. 16 EP. 15: Subsequent Treatment Considerations for Patients with Unsatisfactory Responses to Third-Line Therapy for OAB

This content is intended for US/PR Healthcare Professionals.

The Medical Affairs department of AbbVie Inc. is the sole author and copyright owner of this presentation and has paid Urology Times to host this presentation. AbbVie is solely responsible for all written and oral content within this presentation. © 2023 AbbVie Inc. All rights reserved.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Narmina Khanmammadova, MD, discusses findings on pelvic floor therapy before HoLEP

ByNarmina Khanmammadova, MD

August 12th 2026

Optimizing care for men with overactive bladder, with Keith Xavier, MD

ByKeith Xavier, MD, URPS

August 6th 2026

FDA clears Revi Extend implant for urgency urinary incontinence

ByHannah Clarke

August 5th 2026

Sender Herschorn, BSc, MDCM, FRCSC, on vibegron efficacy in older men with OAB and BPH

BySender Herschorn, BSc, MDCM, FRCSC

July 8th 2026

Retrospective study suggests differences in OAB therapy persistence among older adults

ByUnwanaobong Nseyo, MD, MHS

June 20th 2026

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

Initial prostate cancer presentation, family history linked to survival in mCRPC

Nicole L. Miller, MD, FACS, on persistent LUTS after BPH treatment

Datopotamab deruxtecan enters phase 3 trial in high-risk muscle-invasive urothelial cancer

AI system links surgical gestures with postoperative outcomes

Pearls & Perspectives: From Emergency Medicine to Sexual Medicine, With Jeff Myers, DO